These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 20934572

  • 1. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
    Jones PH, Goldberg AC, Knapp HR, Kelly MT, Setze CM, Stolzenbach JC, Sleep DJ.
    Am Heart J; 2010 Oct; 160(4):759-66. PubMed ID: 20934572
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
    Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Am J Cardiol; 2009 Feb 15; 103(4):515-22. PubMed ID: 19195513
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec 15; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW.
    Curr Med Res Opin; 2008 Mar 15; 24(3):685-94. PubMed ID: 18226326
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
    Barrios V, Amabile N, Paganelli F, Chen JW, Allen C, Johnson-Levonas AO, Massaad R, Vandormael K.
    Int J Clin Pract; 2005 Dec 15; 59(12):1377-86. PubMed ID: 16351668
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    Foody JM, Brown WV, Zieve F, Adewale AJ, Flaim D, Lowe RS, Jones-Burton C, Tershakovec AM.
    Am J Cardiol; 2010 Nov 01; 106(9):1255-63. PubMed ID: 21029821
    [Abstract] [Full Text] [Related]

  • 9. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 01; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2008 Dec 01; 102(11):1489-94. PubMed ID: 19026302
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
    Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2008 Dec 01; 102(11):1495-501. PubMed ID: 19026303
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y.
    Clin Ther; 2006 Jun 01; 28(6):849-59. PubMed ID: 16860168
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
    Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Am Heart J; 2009 Jan 01; 157(1):195-203. PubMed ID: 19081418
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC.
    Am Heart J; 2009 Feb 01; 157(2):352-360.e2. PubMed ID: 19185645
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
    Zieve F, Wenger NK, Ben-Yehuda O, Constance C, Bird S, Lee R, Hanson ME, Jones-Burton C, Tershakovec AM.
    Am J Cardiol; 2010 Mar 01; 105(5):656-63. PubMed ID: 20185012
    [Abstract] [Full Text] [Related]

  • 16. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L, Mata P, Gagné C, Sirah W, Cho M, Johnson-Levonas AO, Meehan A, Troxell JK, Gumbiner B, Ezetimibe Study Group.
    Clin Ther; 2005 Feb 01; 27(2):174-84. PubMed ID: 15811480
    [Abstract] [Full Text] [Related]

  • 17. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
    McKenney J, Ballantyne CM, Feldman TA, Brady WE, Shah A, Davies MJ, Palmisano J, Mitchel YB.
    MedGenMed; 2005 Jul 14; 7(3):3. PubMed ID: 16369229
    [Abstract] [Full Text] [Related]

  • 18. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG, Ballantyne CM, Hsueh W, Rosen J, Lin J, Shah A, Lowe RS, Hanson ME, Tershakovec AM.
    J Clin Lipidol; 2011 Jul 14; 5(6):474-82. PubMed ID: 22108151
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.